PT  - JOURNAL ARTICLE
AU  - Trinh, Nhung TH
AU  - Rostami, Sina
AU  - Pedroncelli, Michele
AU  - Cheesman, Rosa
AU  - Magnus, Per
AU  - Johansson, Stefan
AU  - Andreassen, Ole A.
AU  - Lupattelli, Angela
TI  - Prenatal antidepressant exposure and longitudinal differences in body mass index up to 8 years of age in the offspring born to mothers with pre-pregnancy depressive and/or anxiety in the Norwegian Mother, Father and Child Cohort Study
AID  - 10.1101/2024.07.09.24310139
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.09.24310139
4099  - http://medrxiv.org/content/early/2024/07/10/2024.07.09.24310139.short
4100  - http://medrxiv.org/content/early/2024/07/10/2024.07.09.24310139.full
AB  - Importance No study with available data from birth into late childhood has explored how prenatal antidepressant exposure affects offspring body mass index (BMI) throughout childhood.Objective To determine the association between prenatal antidepressant exposure and longitudinal differences in child BMI up to age 8 years.Design, Setting, and Participants We used data from the Norwegian Mother, Father, and Child Cohort Study (MoBa) linked to the Medical Birth Registry of Norway and the MoBa Genetics. We included 6,084 pregnancy-child dyads (singleton, liveborn) with available parent-reported data on child BMI from birth up to 8 years of age, born to women with depression/anxiety prior to pregnancy. Analysis was performed between January 2023 and April 2024.Exposures Prenatal antidepressant exposure was categorized as i) continued antidepressants in pregnancy (n=626); ii) discontinued antidepressants proximal to pregnancy (n=412); or iii) unexposed to antidepressants both before and during pregnancy (n=5,046).Main outcomes and measures Child BMI up to 8 years of age. Mean BMI differences over time across antidepressant exposure groups were compared using multilevel mixed-effect linear models.Results Children born to mothers who continued antidepressant into pregnancy had comparable childhood BMIs with those born to unexposed mothers or mothers who discontinued antidepressant proximal to pregnancy. Higher BMI was observed up to 3 years of age among male offspring born to antidepressant continuers compared to discontinuers, especially in those exposed to selective-serotonin-reuptake-inhibitor before pregnancy (mean difference in BMI, β=0.334; 95% CI: 0.081 to 0.588 at baseline). Lower BMI was seen among female offspring born to continued vs. discontinued mothers and the gap became larger over time, especially between low-moderate use of antidepressant vs. discontinuation during pregnancy. Analyses integrating parental genetic liability for depression, BMI, and antidepressant response using polygenic risk scores in a sub-population (n=1,913) suggests potential influence of the genetic component on the differences in BMI across antidepressant trajectory groups in some strata.Conclusion and relevance The longitudinal childhood BMI of children born to mothers with pre-pregnancy depression/anxiety did not differ across prenatal antidepressant exposure trajectories. Exploratory analyses revealed differences at specific time frames which might be sex-specific and potentially influenced by genetic liability profiles.Question Does prenatal antidepressant exposure affect longitudinal childhood BMI?Findings In this cohort study of 6084 pregnancy-child dyads in mothers with pre-pregnancy depressive/anxiety disorders, no difference in longitudinal childhood BMI across prenatal antidepressant exposure groups were observed. Exploratory analyses revealed differences at specific time frames which might be sex-specific and potentially influenced by parental genetic liability profiles.Meaning Longitudinal BMI throughout childhood of children born to mothers with pre-pregnancy depression/anxiety did not differ across prenatal antidepressant exposure trajectories. Further research is needed to investigate the time-dependent, sex-specific, and genetic-related aspects of some strata of antidepressant exposure on BMI differences.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work, Nhung Trinh and Angela Lupattelli are supported by the Norwegian Research Council (grant no. 288696).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was approved by The Regional Committees for Medical and Health Research Ethics on 12th February 2020 (reference number: 63566/REK South East), and by the Norwegian Data protection agency (reference number: 672954).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDue to Norwegian legislation, the researcher cannot make the data material on an individual level available to others at any time, including in connection with publication. According to the regulations in Norway and the National Institute of Public Health, no MoBa data on an individual or aggregated level may be uploaded into any repository or database at any time. Data from the Norwegian Mother, Father and Child Cohort Study and the Medical Birth Registry of Norway used in this study are managed by the national health register holders in Norway (Norwegian Institute of Public Health) and can be made available to researchers, provided approval from the Regional Committees for Medical and Health Research Ethics (REC), compliance with the EU General Data Protection Regulation (GDPR) and approval from the data owners. The consent given by the participants does not open for storage of data on an individual level in repositories or journals. Researchers who want access to data sets for replication should apply through helsedata.no.